Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - lanreotide (lanreotide acetate) - solution (extended release) - 90mg - lanreotide (lanreotide acetate) 90mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - lanreotide (lanreotide acetate) - solution (extended release) - 120mg - lanreotide (lanreotide acetate) 120mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - abobotulinumtoxina - powder for solution - 300unit - abobotulinumtoxina 300unit - other miscellaneous therapeutic agents

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - abobotulinumtoxina - powder for solution - 500unit - abobotulinumtoxina 500unit - other miscellaneous therapeutic agents

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - abobotulinumtoxina - powder for solution - 300unit - abobotulinumtoxina 300unit - other miscellaneous therapeutic agents

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - irinotecan (irinotecan sucrose octasulfate) - suspension - 4.3mg - irinotecan (irinotecan sucrose octasulfate) 4.3mg - antineoplastic agents

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ep plus group sdn. bhd. - diosmectite -

European Union - English - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastic agents - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 20mg - cabozantinib (cabozantinib malate) 20mg - antineoplastic agents

Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 40mg - cabozantinib (cabozantinib malate) 40mg - antineoplastic agents